# Phase 0 completion record

- Completion date: 2026-09-17
- Scope: private development
- Accountable owner: joshuamyers22

| Required deliverable | Status | Evidence |
|---|---|---|
| Approved project brief and governance model | Complete for private development | `PROJECT_BRIEF.md`; `governance/GOVERNANCE.md` |
| ADR-001 through ADR-004 | Accepted | `docs/adr/ADR-001-independent-oracle.md` through `ADR-004-compatibility-contract.md` |
| Deterministic local-source manifest | Complete: 363 files, 2,505,213 bytes | `reference/manifests/rms-8.2-0-files.sha256` |
| Immutable R source identity | Complete: byte-identical upstream commit recorded | `REFERENCE_SOURCE.md`; ADR-003 |
| Dependency/container manifest | Complete for the arm64 oracle | `reference/r/Dockerfile`; `reference/expected/oracle-environment.json` |
| Namespace, S3, and native routine inventory | Complete: 121 exports, 160 S3 methods, and six registered Fortran routines | `reference/manifests/rms-8.2-0-inventory.json` |
| Initial capability tiers and ownership | Complete: 281/281 entries | `compatibility/rms-8.2.0.yaml` |
| Provenance and contribution process | Complete | `governance/PROVENANCE.md`; `CONTRIBUTING.md` |
| Staffing, review, budget, and release definitions | Complete as an explicit constrained plan | `governance/GOVERNANCE.md`; project-plan approval record |
| Risk register and threat model | Complete for current scope | `governance/RISK_REGISTER.md`; `governance/THREAT_MODEL.md` |

## Exit-gate disposition

- Private independent-development path: approved.
- Rebuildable and hashed reference environment: passed on arm64 Linux.
- Public namespace ownership/triage: passed for 281 of 281 entries.
- External distribution: blocked pending a qualified license/provenance reviewer
  and name/trademark clearance.
- Capability promotion beyond `experimental`: blocked pending the applicable
  scoped statistical, numerical, and independent-verification reviews. Phase 3
  subsequently received its scoped statistical approval, but the other reviews
  remain open.

The two blockers do not prevent Phase 1 laboratory work. They do prevent public
artifacts and stronger compatibility claims. They may not be waived by changing
documentation or test labels.
